Drug Interactions
Active Resources: 19
Clinical Reference Tools
-
2/1/2018
-
5/3/2017 (reviewed: 5/3/2017)
Antiretroviral Guidelines
-
10/27/2017
Online Training
-
10/20/2017
-
7/13/2017
-
5/1/2016
Slide Sets
-
4/28/2017
-
4/28/2017
Webinar Recordings
-
1/12/2017
Online and Self-Paced Learning
-
12/7/2016
-
11/16/2016
-
10/12/2016
Charts, Tables & Posters
-
7/1/2016
-
1/28/2015
Image Library
-
4/6/2016
Toolkits
-
4/29/2015
Pocket Guides
-
4/1/2015
-
2/1/2014
Coinfection Guidelines (Hep, TB, STIs)
-
3/27/2014 (reviewed: 10/31/2016)
Archive Resources: 15
Pocket Guides
-
7/1/2013
-
4/1/2013
-
9/15/2009
-
1/1/2008
Coinfection Guidelines (Hep, TB, STIs)
-
6/1/2013
Webinar Recordings
-
2/19/2013
Charts, Tables & Posters
-
1/1/2013
Curricula
-
11/1/2012
-
10/1/2008
Slide Sets
-
6/12/2012
-
6/1/2011
-
6/1/2011
-
3/1/2006
-
1/1/2006
Videos
-
11/9/2011
Articles: 5
-
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)
Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain...
-
Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference
Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair
The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...
-
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...
-
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and...
-
Pitavastatin and Darunavir/Ritonavir
Coauthor: Susa Coffey, MD; Medical Editor, AETC National Resource Center
Treatment of dyslipidemia is often complicated by drug interactions between statins and antiretrovirals. Pitavastatin is one of the newer statins approved and is one of the few that is not...
| Day | Title |
|---|---|
|
5/10 |